Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.

© Shutterstock
Endocannabinoid signalling is increasingly recognised as fundamentally important in the development and function of the nervous system. This exciting programme of work has the potential to lead to the development of novel therapies for neurological disorders.’
- Associate Professor in Clinical Neurosciences, Zameel Cader

The programme aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.

Through an initial investment of up to £10 million provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.

Read more...

Similar stories

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.